PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study

Documenti analoghi

• Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
  di: Peng Gao, et al.
  Pubblicazione: (2025)
• Clinical Benefit of PD‐1/PD‐L1 Inhibitors as Standard First‐Line Treatment in Low PD‐L1‐Expressing Advanced Solid Tumors: A Systematic Review and Meta‐Analysis
  di: Peng Wu, et al.
  Pubblicazione: (2026)
• Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
  di: Jia Yu, et al.
  Pubblicazione: (2025)
• Sulforaphane Synergizes With PD‐1 Blockade Through Activating CD8 + T Cells in Non–Small Cell Lung Cancer: Preclinical and Clinical Investigations
  di: Jieyao Li, et al.
  Pubblicazione: (2026)
• Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy
  di: Xinmin Wang, et al.
  Pubblicazione: (2025)